Despite existing treatments and recent advances in potential targets for pharmacological interventions, there remains a great unmet need in the treatment of Alzheimer's disease (AD). Progress toward new therapeutic agents is hampered by diffi culties in the related issues of measurement of disease/symptom pathology and prediction of disease course, both of which impact many facets of drug development including study design, power and sample size calculations, and interpretability of results. Diffi culties in measurement and prediction are even more pronounced when moving into a milder or presymptomatic patient population.
Introduction
Despite existing treatments and recent advances in potential targets for pharmacological interventions, there remains a great unmet need in the treatment of Alzheimer's disease (AD). Progress toward new therapeutic agents is hampered by diffi culties in the related issues of measurement of disease/symptom pathology and prediction of disease course, both of which impact many facets of drug development including study design, power and sample size calculations, and interpretability of results. Diffi culties in measurement and prediction are even more pronounced when moving into a milder or presymptomatic patient population.
A symposium held at the Clinical Trials in Alzheimer's Disease conference in Monte Carlo, Monaco (29 to 31 October 2012) dealt with some of these issues, emphasiz ing the potential of diff erent modeling approaches. Modeling the course of AD at diff erent stages of its development, from the presymptomatic stages to severe dementia, is assumed to contribute to better planning and design of future clinical trials. ree diff erent approaches using patient populations from across the diagnostic spectrum of the disease -probable/possible AD, mild cognitive impair ment (MCI) and amnestic MCI -were presented and are summarized in the following paragraphs.
Predicting progression of Alzheimer's disease: understanding the variance in progression of AD (Rachelle Doody)
In their pioneering work, Rachelle Doody and colleagues assert that modeling of group disease progression is critical for estimating change in clinical trials of diseasemodifying therapies. Despite years of observation in small studies, there is no clear model for how AD progresses or for the sources of variance in progression between patients. According to these authors, multivariate models of disease progression can also identify the factors that contribute to the variance and thereby foster the ability to stratify patients in clinical trials or to predict progression in individual patients. Doody and her group have shown that an estimate of early disease progression, the pre-progression rate, is predictive of the time it will take to develop substantial decline [1] .
Doody and her group have also used mixed-eff ects regression analysis to examine the role of demographic, biological, clinical and psychometric characteristics in predicting progression of AD in a large patient cohort [2] .
is work suggests that premorbid IQ (probably a surrogate for cognitive reserve) and the early, intrinsic progression rate are the most predictive variables, yet these are seldom captured as baseline characteristics and are therefore seldom balanced or accounted for in the analysis of clinical trials. e persistence of anti-dementia drug use from the time of symptom onset is also a predictive variable [3] , whereas most study protocols simply collect information on concurrent drug use at the time of randomization. Although the pre-progression
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Although the Doody group has been modeling the progression rate for some time, the question of interindividual variance in progression rates is a new focus of investigation. e new analysis suggests that the factors contributing most to variance in outcomes -such as the Alzheimer Disease Assessment Scale cognitive (ADAScog), Clinical Dementia Scale Sum of Boxes (CDR-SB), Instrumental Activities of Daily Life, Physical Self-Maintenance Scale, and Mini Mental State Examination (MMSE) -are the pre-progression rate, the presence or development of parkinsonism, and the presence or development of psychosis. In their multivariable model, which includes time, the American National Adult Reading Test estimate of IQ, the progression rate and the presence or development of parkinsonism or psychosis, one-third to one-half of variance between individuals was explained, depending on which outcome (MMSE, ADAS, CDR-SB, Physical Self-Maintenance Scale, Instrumental Activities of Daily Life) was considered.
Taken together, the studies on progression rates and variance suggest that patients should be stratifi ed based upon IQ and pre-progression rate (as opposed to MMSE), and that studies should capture the development of parkinsonism or psychosis for use as time-dependent covariates in the comparison of treatment groups. Studies should probably also quantify disease-long exposure to anti-dementia drugs, as opposed to simply recording their use during the clinical trial. Although the potential for enriching clinical trials populations through the use of IQ and pre-progression rates also exists, the authors would not recommend this until their eff ects in treatment trials are better understood.
Creating a new composite score for optimizing responsiveness to decline in early AD and very early AD (Suzanne Hendrix)
Suzanne Hendrix has proposed empirically derived composite outcome scores that optimize the power for measur ing clinical disease progression for trials in MCI and pre-MCI populations [4] . e goal of this work is to improve the responsiveness of clinical outcomes to disease progression in early stages of AD, with the expectation that this will give treatments the best chance for showing an eff ect. e proposed composite outcome scores for MCI utilize items from standard AD instruments, such as the ADAS-cog, but rather than summing all item scores they use an optimization algorithm to select and weigh the items that are declining most in the population of interest, excluding items that are not yet declining in these early AD populations.
Approaches based on principal components factor analysis and diff erent regression techniques have been compared for robustness over multiple study datasets and across enriched (amyloid beta 42-positive, apolipoprotein E4 allele carriers) and non-enriched populations. When ADAS-cog, MMSE and CDR-SB items are considered, similar item combinations are identifi ed as responsive to disease progression despite the diversity of the populations and methodology, indicating that the majority of MCI subjects in clinical studies have a common symptom profi le over time. e items that are common across populations and methodologies are delayed word recall and orientation from the ADAS-cog, orientation to time from the MMSE and all six CDR box scores.
e partial least-squares model -which is a compromise between an item response theory or principal components approach and an approach that directly optimizes the sensitivity to changes over timeappears to result in the most robust combinations, and excludes redundant items with lower responsiveness from the composite score. is method also estimates the optimal weighting of the items to refl ect the relative importance of each item in the population under consideration.
Composite scores can be constructed utilizing cognitive items only, global or functional items only or a combination for optimal responsiveness. is methodology could also be applied to biomarker data in order to identify which biomarkers measure decline that is not redundant with clinical outcomes. ese responsive composite clinical outcomes allow smaller and shorter clinical trials in early disease, and will help with validation of biomarkers in these early stages. Population enrichment provides additional improvement over item optimization alone [5] , but optimizing within an enriched population does not result in substantially diff erent item combinations, indicating that the methodology successfully identifi es the disease-specifi c decline across homogeneous or heterogeneous MCI patient populations.
The placebo group simulation approach: an alternative to long-term placebo-controlled trials (René Spiegel)
René Spiegel presented his teams' development work on the placebo group simulation approach (PGSA), a novel clinical study design for use in long-term trials with putative disease-course altering drugs for use in AD. e PGSA is intended to circumvent a major limitation of randomized placebo-controlled double-blind clinical trial designs; that is, the need to expose prodromal AD patients at high risk for dementia to extended placebo treatment, which may result in problems with patient recruitment [6] , questions about the representativeness of study samples and ethical issues. e PGSA uses stochastic modeling to forecast predefi ned endpoints and trajectories of neuropsycho logical outcomes from the data that are routinely available at the outset of clinical trials: basic demographic, biological and neuropsychological data for all study participants. ese model-based, forecasted endpoints and trajectories of the study sample constitute the background -the simulated placebo group -against which potential drug eff ects can be contrasted.
Development and initial testing of PGSA algorithms for the ADAS-cog and the composite score of a neuropsychological test battery (NP-Batt9) using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI 1) MCI patient cohort [7] were described in Spiegel and colleagues [8] . A new analysis of data from the ADNI 1 AD patient cohort, using the published PGSA algorithm for the NP-Batt9, confi rms the high concordance between the model-based forecasted data and the actually observed neuropsycho logical data (Figure 1 ) and supports the application of the PGSA algorithm for the neuropsychological test battery used in ADNI 1 over a wide spectrum of preclinical and clinical AD patients [9] . e PGSA algorithm developed from the ADNI 1 MCI database was then adapted to a modifi ed neuro psychological battery and applied to data from amnestic MCI patients available in the National Alzheimer's Coordination Center database (grant number U01 AG016976). e results obtained from this larger and less narrowly defi ned patient sample confi rm that mathematically modeled trajectories of neuropsychological measures show high concordance with the empirically observed outcomes in amnestic MCI patients. Based on these retrospective analyses of publicly available data from large MCI and AD patient samples, Spiegel and colleagues thus conclude that the PGSA algorithms for the ADAS-cog and a NP-Batt allow valid forecasts of the distribution of the trajectories and endpoints of relevant neurocognitive outcomes recorded from amnestic MCI and symptomatic AD patients. Pending further confi rmatory studies in international sets of data, prospective studies should be performed, preferably in the context of real-life anti-AD drug development. Given their inherent limitations (focus on quantifi ed indices of effi cacy, lack of concomitant controls for potential drug side eff ects), PGSA-based trials are expected to complement random ized placebo-controlled trials in the later phases of anti-AD drug development; that is, at stages when there is adequate evidence of a drug's effi cacy and safety available from preceding placebo-controlled clinical studies.
Discussion (Kristin Kahle-Wrobleski)
e diffi culties of measurement and prediction in AD are not easily fi xed given the inherent complexities of the disease state. ese complexities notwithstanding, consensus within the scientifi c community on favorable approaches for modeling and predicting disease course is necessary to help regulatory and payor agencies make informed decisions about the approvability and accessibility of the next generation of pharmacological interventions. e approaches listed are important anchor points for building this consensus and provide relatively straightforward suggestions for improving measurement and prediction in AD: control for as many known variables as possible; use the most sensitive items/scales possible; and use modeling whenever possible to minimize the number of patients needed in trials.
Doody and colleagues draw on an extensive literature as well as their own institutional research to suggest a set of measures that are easily adapted for use in clinical trials, including premorbid IQ and persistence of treatment with cholinesterase inhibitors/memantine (not just a binary variable of use). Furthermore, the time since onset of symptoms can help model individual trajectories of progression to inform models. Hendrix similarly looks at time as a crucial variable to inform how best to maximize the sensitivity of current scales. With this approach, scale items are retained in a composite only if those items are strongly related to progression over time. Existing scales can therefore be combined to move away from thinking of scales as tools of staging or description, towards using scales as more powerful and sensitive instruments that can shorten trial times and reduce the number of patients needed to enroll in trials. Spiegel and colleagues also sought to fi nd ways to minimize the number of patients needed in trials and exposed to longterm placebo treatment. eir approach, like Doody and colleagues and Hendrix and colleagues, uses existing scales to build a simulated placebo group that could be used instead of an actual placebo group for trials in advanced stages of drug development.
As with most modeling approaches, additional validation is needed in a variety of datasets before a gold standard is likely to be declared. Most of the datasets used to inform these approaches come from highly specialized centers that see patients who are unlikely to represent the broader patient population. Conceptually, these approaches should apply to international patient populations, and additional validation work with datasets from various countries (for example, European Alzheimer's Disease Consortium, Australian Imaging, Biomarker, and Lifestyle Flagship Study of Ageing) might provide evidence of generalizability. Other benefi cial validation work may look at what, if any, diff erences exist in model fi t when diff ering diagnostic criteria [10] [11] [12] are used to select patient cohorts. Further, as biomarkers evolve and the fi eld becomes better able to distinguish underlying neuropathologies, models of clinical symptoms are likely to need further refi nement. Another key consideration when evaluating the impact of these modeling approaches is that the purpose of clinical trials is not just to show benefi t of a drug; the trials should also characterize and quantify the risks associated with the therapy. Discussions with regulators and payors will therefore be needed to help industry sponsors understand how best to collect safety data within the context of shorter studies or potentially, as Spiegel and colleagues suggest, in the absence of a long-term placebo group that might inform base rates of events.
Although alternative approaches using new scales have been suggested as a way of improving the speed and accuracy of trials (for example [13] ), the modeling approaches described here make use of scales widely used in clinical trials, patient registries and observational studies. e advantage of using existing scales versus creating new ones is not inconsequential. ese approaches more easily allow validation with complimentary datasets and also facilitate comparisons between the approaches. In discussions with regulatory and payor agencies, it is also helpful to include measures with a substantial research history across a variety of settings so that discussions can productively focus on assessing benefi ts and risks rather than debating measurement methodology. Modeling approaches such as the ones described here help provide stakeholders with pragmatic solutions to running trials that may be fairly easy to implement and provide additional rigor for detecting drug eff ects in a more timely manner.
Conclusion
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